TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06760819: A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human E

Sponsor: Bayer · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 111 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT06760819 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06760819 Rescue Dossier →